Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached

February 24, 2020 8:30 AM

Further Extends Company's Biologic Market OpportunitiesJUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced...

Read more

Molecular Partners to Present at Two Upcoming Healthcare Investor Conferences

February 24, 2020 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 24, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced that senior management will present at two upcoming healthcare investor conferences. Conference Presentation Details: Event: SVB Leerink 9th Annual Global Healthcare Conference Date/Time: Wednesday, February 26, 2020...

Read more

Mota Ventures Announces Transition After Definitive Close of First Class CBD Acquisition; Ryan Hoggan is New CEO

February 22, 2020 6:05 AM

VANCOUVER, BC / ACCESSWIRE / February 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company" or "Mota") is pleased to announce a transition after the definitive close of First Class CBD acquisition, the Company's Board of Directors has appointed Ryan Dean Hoggan to Chief Executive Officer. The acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company's European CBD...

Read more

DECN Announces Market Readiness of Its GenUltimate TBG, Adds To Product's Compatibility at The Request Of Strategic Partner, Completes Its Universal Translator GenExpidient! Device

February 20, 2020 8:55 AM

Company posts initial forecast for its new GenAccord!, moves two new products GenUltimate! precis TBG and GenCambre! into advanced development, readies patents for GenUltimate TBG & GenExpidient! LOS ANGELES, CA / ACCESSWIRE / February 20, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device...

Read more

Molecular Partners Announces Newly Nominated Board Members for Upcoming Annual Meeting

February 20, 2020 1:00 AM

Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General Meeting Nominees bring extensive expertise in the fields of oncology drug discovery, translational science, clinical development, portfolio management, commercial product launch, and capital formation. Goran Ando, William Lee and Petri Vainio will not stand for re-election after...

Read more

Frelii Provides Update on GATC Canna Revenue Sharing Agreement

February 14, 2020 7:30 AM

Multiple acquisitions to drive significant growth of customer base LEHI, UT / ACCESSWIRE / February 14, 2020 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update regarding its previously announced revenue sharing agreement with GATC Canna Corp....

Read more

Edesa Biotech Reports Fiscal 1st Quarter 2020 Results

February 13, 2020 4:10 PM

TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 and provided an update on its business. During the quarter, Edesa expanded an ongoing Phase 2b study of its lead product candidate, EB01, following positive safety data in healthy volunteers. The company is developing EB01 as a monotherapy...

Read more

Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

February 13, 2020 8:00 AM

Leading research expert in developing new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapy Dr. Mamonkin is a faculty member in the Center for Cell and Gene Therapy at Baylor College of Medicine FRAMINGHAM, MA / ACCESSWIRE / February 13, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™,...

Read more

Midatech Pharma PLC Announces Notice of General Meeting

February 12, 2020 9:50 AM

Midatech Pharma announces posting of Circular convening a General Meeting Share Consolidation and ADR Ratio Change ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 12, 2020 / Midatech Pharma PLC (AIM:MTPH.L) (NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that it will today publish a circular to shareholders ("Circular") containing a notice...

Read more

Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference

February 11, 2020 8:05 AM

Presentation on Tuesday, February 18th 2020 at 2:30 p.m. ET FRAMINGHAM, MA / ACCESSWIRE / February 11, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic,...

Read more

Hemagenetics Technologies Corp. Announces Resignation and Appointment of New Director and CFO

February 6, 2020 5:30 PM

VANCOUVER, BC / ACCESSWIRE / February 6, 2020 / Hemagenetics Technologies Corp. (the "Company" or "HTC") announces that Ronald Ozols has resigned effective immediately as director and CFO and Mr. Patrick Brown has been appointed as his replacement. Bio for new director and CFO: Patrick Brown Mr. Brown, 53, is an experienced and formally trained Chartered Accountant with over 25 years in senior audit and finance...

Read more

ZIVO Bioscience Announces Impressive Results for Poultry Gut Health Studies Conducted in Q3/Q4 2019 Utilizing Proprietary Algal Biomass as Feed Ingredient

February 6, 2020 8:00 AM

KEEGO HARBOR, MI / ACCESSWIRE / February 6, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, announces today that several poultry gut health studies conducted in the last two quarters of 2019 have yielded statistically significant and repeatedly successful results across five (5) different research studies performed at...

Read more

Mota Ventures Enters into Letter of Intent to Form Joint Venture with BevCanna Enterprises

February 6, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / February 6, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") is excited to announce it has entered into a letter of intent (the "LOI"), dated February 5, 2020, with BevCanna Enterprises Inc. ("BevCanna") (CSE:BEV), an arms'-length party. Under the terms of the LOI, the parties will negotiate a joint venture, which is expected to provide the Company with...

Read more

Molecular Partners Reports Key Financials for FY 2019 and Corporate Highlights from Q4 2019

February 6, 2020 1:00 AM

Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA and EMA filings accepted and under review MP0250 (VEGF x HGF) in Multiple Myeloma: Updated data presented at ASH in...

Read more

Dyadic to Present at Two Upcoming Conferences

February 5, 2020 4:15 PM

JUPITER, FL / ACCESSWIRE / February 5, 2020 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following investor conferences:BIO CEO & Investor Conference Marriott Marquis New York City, NYMonday, February 10, 2020 2:15 p.m. ETNobleCon16 Seminole Hard Rock Hotel & Casino Hollywood, FLMonday, February 17, 2020 2:30 p.m....

Read more

Players Network, Inc. Shareholder 2019 Year in Review and 2020 Outlook

February 5, 2020 8:05 AM

Green Leaf Farms International is Raising Capital in Their Founders Round. LAS VEGAS, NV / ACCESSWIRE / February 5, 2020 / Player's Network, Inc. (OTCPINK:PNTV), a rapidly growing international company in the adult-use and medical marijuana industry, with operations in Las Vegas, Nevada and Jujuy Argentina, published a Shareholder update from CEO Mark Bradley. Please visit this link https://playersnetwork.com/2019-year-in-review/ to...

Read more

Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020

January 31, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more

Mota Ventures Recap of First Class Conference Call

January 30, 2020 8:00 AM

VANCOUVER, BC / ACCESSWIRE / January 30, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") would like to thank all shareholders and investors for attending yesterday's conference call. The main items addressed on the call were the revenue, profit margins and the short- and long-term growth plans of First Class CBD ("First Class"), a wholly owned subsidiary of the Company. The conference call...

Read more

Dyadic Interviewed with FOX Business Network

January 28, 2020 9:50 AM

JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more

1933 Industries Engages Market Makers

January 27, 2020 10:00 PM

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQX:TGIFF), a vertically-integrated and growth-orientated cannabis consumer packaged goods company, announces that it has retained the services of PI Financial Corp. ("PI") and Independent Trading Group ("ITG") for market making services in accordance with the Canadian Securities Exchange...

Read more